Sage Journals: Discover world-class research

Abstract

Background. Decision makers often need to assess the real-world effectiveness of new drugs prelaunch, when phase II/III randomized controlled trials (RCTs) but no other data are available. Objective. To develop a method to predict drug effectiveness prelaunch and to apply it in a case study in rheumatoid arthritis (RA). Methods. The approach 1) identifies a market-approved treatment (S) currently used in a target population similar to that of the new drug (N); 2) quantifies the impact of treatment, prognostic factors, and effect modifiers on clinical outcome; 3) determines the characteristics of patients likely to receive N in routine care; and 4) predicts treatment outcome in simulated patients with these characteristics. Sources of evidence include expert opinion, RCTs, and observational studies. The framework relies on generalized linear models. Results. The case study assessed the effectiveness of tocilizumab (TCZ), a biologic disease-modifying antirheumatic drug (DMARD), combined with conventional DMARDs, compared to conventional DMARDs alone. Rituximab (RTX) combined with conventional DMARDs was identified as treatment S. Individual participant data from 2 RCTs and 2 national registries were analyzed. The model predicted the 6-month changes in the Disease Activity Score 28 (DAS28) accurately: the mean change was -2.101 (standard deviation [SD] = 1.494) in the simulated patients receiving TCZ and conventional DMARDs compared to -1.873 (SD = 1.220) in retrospectively assessed observational data. It was -0.792 (SD = 1.499) in registry patients treated with conventional DMARDs. Conclusion. The approach performed well in the RA case study, but further work is required to better define its strengths and limitations.

Keywords

effect modifier efficacy-effectiveness gap prognostic factor prediction model rheumatoid arthritis treatment predictor

Get full access to this article

View all access options for this article.

References

Cole

Stuart

EA.

Generalizing evidence from randomized clinical trials to target populations: the ACTG 320 trial. Am J Epidemiol. 2010;172(1):107–15.

Drummond

Schwartz

Jönsson

et al . Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24(3):244–58.

Nordon

Karcher

Groenwold

et al . The “efficacy-effectiveness gap”: historical background and current conceptualization. Value Health. 2016;19(1):75–81.

Eichler

H-G

Abadie

Breckenridge

et al . Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10(7):495–506.

McDermott

Downing

Stratton

MR.

Genomics and the continuum of cancer care. N Engl J Med. 2011;364(4):340–50.

Tannen

Weiner

Xie

Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ. 2009;338:b81.

Panayidou

Gsteiger

Egger

et al . GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world. Res Synthesis Methods. In press.

Levy

WC.

The Seattle heart failure model: prediction of survival in heart failure. Circulation. 2006;113(11):1424–33.

Ponikowski

Voors Anker

et al . 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.

10.

Yancy

Jessup

Bozkurt

et al . 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240–e327.

11.

GetReal consortium. IMI GetReal—real-life data in drug development. Available from: http://www.imi-getreal.eu/

12.

Egger

Moons

KGM

Fletcher

GetReal Workpackage 4. GetReal: from efficacy in clinical trials to relative effectiveness in the real world. Res Synthesis Methods. 2016;7:278–81.

13.

Pile

Graham

Mahler

SM.

Disease-modifying anti-rheumatic drugs. In: Parnham

, ed. Encyclopedia of Inflammatory Diseases. Basel, Switzerland: Springer Basel; 2015. p 1–13.

14.

Genovese

McKay

Nasonov

et al . Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug. Arthritis Rheum. 2008;58(10):2968–80.

15.

Cohen

Emery

Greenwald

et al . Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–806.

16.

Langenegger

Fransen

Forster

Seitz

Michel

BA.

Klinisches Qualitätsmanagement bei der Rheumatoiden Arthritis. Zeitschrift Rheumatol. 2001;60(5):333–41.

17.

Dennison

Packham

Hyrich

The BSRBR-RA at 15 years: providing real-world insight into the effectiveness and safety of biologic therapies. Rheumatology. 2016;55(12):2093–5.

18.

Fransen

Stucki

van Riel

PLCM

. Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Rheum. 2003;49(S5):S214–24.

19.

Gabay

Emery

van Vollenhoven

et al . Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–50.

20.

Tannenbaum

Holford

NHG

Lee

Peck

Mould

DR.

Simulation of correlated continuous and categorical variables using a single multivariate distribution. J Pharmacokinet Pharmacodynam. 2006;33(6):773–94.

21.

Tibshirani

Regression shrinkage and selection via the lasso: a retrospective: regression shrinkage and selection via the lasso. J R Stat Soc B. 2011;73(3):273–82.

22.

Swets

JA.

Measuring the accuracy of diagnostic systems. Science. 1988;240(4857):1285–93.

23.

Friedman

Hastie

Tibshirani

Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.

24.

Robin

Turck

Hainard

et al . pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12(1):77.

25.

Crowson

Matteson

Davis

Gabriel

SE.

Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res. 2013;65(1):71–77.

26.

Austin

van Klaveren

Vergouwe

Nieboer

Lee

Steyerberg

EW.

Geographic and temporal validity of prediction models: different approaches were useful to examine model performance. J Clin Epidemiol. 2016;79:76–85.

27.

Gelman

Carlin

Stern

Dunson

Vehtari

Rubin

DB.

Bayesian Data Analysis. 3rd ed.Boca Raton, FL: CRC Press/Chapman & Hall; 2014.

28.

EFPIA MID3 Workgroup, Marshall

Burghaus

et al . Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT Pharmacometrics Syst Pharmacol. 2016;5(3):93–122.

29.

Debray

TPA

Moons

van Valkenhoef

et al . GetReal in individual participant data (IPD) meta-analysis: a review of the methodology. J Res Synthesis Methods. 2015;6(4):293–309.

30.

Efthimiou

Debray

van Valkenhoef

et al . GetReal in network meta-analysis: a review of the methodology. Res Synthesis Methods. 2016;7(3):236–63.

31.

Hernan

Robins

JM.

Causal Inference. Boca Raton, FL: CRC; 2017.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.58 MB

Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis

Abstract

Keywords

Get full access to this article

References

Supplementary Material